Cardiff-by-the-Sea, CA, United States of America

Benjamin Jones

USPTO Granted Patents = 27 (Patent Applications = 11)

CIPO Patents = 4 (Patent Applications = 9)

EPO Patents = 12 (Patent Applications = 14)

Average Co-Inventor Count = 7.3

ph-index = 6

Forward Citations = 115(Granted Patents)

Location History:

Hamden, CT (US) (2006 - 2011)
New Haven, CT (US) (2009 - 2012)
Turlock, CA (US) (2017)
Cardiff-by-the-Sea, CA (US) (2011 - 2019)
San Diego, CA (US) (2013 - 2023)

Company Filing History:

16 out of 1,177

Takeda Pharmaceutical Company Limited

patents

4 out of 70

Bayer Pharmaceuticals Corporation

Bellwether Coffee Co.

Years Active: 2006-2024

where 'Filed Patents' based on already Granted Patents

27 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12162893 - Tricyclic pyridones and pyrimidones (2024-12-10),

2. 11845761 - Tricyclic pyridones and pyrimidones (2023-12-19),

3. 11426397 - Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 (2022-08-30),

4. 10407409 - 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD (2019-09-10),

5. 10362798 - Roasting system with clean emissions and high thermal efficiency (2019-07-30),

6. 9944626 - 6-(5-hydroxy-1H-pyrazol-1-YL)nicotinamide inhibitors of PHD (2018-04-17),

7. 9708296 - 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD (2017-07-18),

8. 9669966 - Method and apparatus for wine bottle packaging and display (2017-06-06),

9. 9345713 - 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD (2016-05-24),

10. 9187497 - Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP) (2015-11-17),

11. 9181255 - Fused heteroaromatic pyrrolidinones as SYK inhibitors (2015-11-10),

12. 9108970 - Fused heteroaromatic pyrrolidinones (2015-08-18),

13. 9040522 - 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD (2015-05-26),

14. 8822470 - Substituted pyrido[2,3-b]pyrazines (2014-09-02),

15. 8450323 - Substituted derivatives of pyrido[3,2-e][1,4]thiazino[4,3-a]pyrazine and pyrido[3,2-e][1,4]oxazino[4,3-a]pyrazine (2013-05-28),

Title: Benjamin D Jones: A Pioneer in Pharmaceutical Innovations

Introduction:

Benjamin D Jones, a prolific inventor based in New Haven, CT, has made significant contributions to the field of pharmaceuticals with a total of 7 patents to his name. His groundbreaking work focuses on developing compounds for treating hyper-proliferative disorders and diseases associated with angiogenesis.

Latest Patents:

Jones' latest patents include pyrrolotriazine derivatives that show promise in the prevention and treatment of hyper-proliferative disorders linked to angiogenesis. Additionally, his 2-oxo-1,3,5-perhydrotriazapine derivatives offer potential solutions for hyper-proliferative, angiogenesis, and inflammatory disorders.

Career Highlights:

Having worked at Bayer Pharmaceuticals Corporation and Bayer Healthcare LLC, Jones has honed his expertise in developing novel pharmaceutical compounds. His innovative approach to drug discovery has garnered recognition within the industry for its potential to revolutionize treatment methods.

Collaborations:

Throughout his career, Jones has collaborated with esteemed colleagues such as Barton W Phillips and Jacques P Dumas. These partnerships have fostered creativity and knowledge exchange, leading to the successful development of cutting-edge pharmaceutical solutions.

Conclusion:

Benjamin D Jones stands as a pioneering figure in the realm of pharmaceutical innovations, with a commendable track record of patents that address critical medical needs. His collaborations and career milestones underscore his dedication to advancing healthcare through inventive solutions.

This text is generated by artificial intelligence and may not be accurate.